Active Biotech Year-End Report January-December 2007

"During the year, the US and European regulatory authorities approved laquinimod for Phase III and recruitment of patients could commence. Consequently, we passed an important milestone in the development of a safe and effective product. Together with four additional products in clinical phases, we thus strengthened Active Biotech's position as a company with a balanced and mature project portfolio."

 

For further information, please contact:

 

Sven Andréasson

President and CEO

Tel +46 (0)46-19 20 49

Cecilia Hofvander                               

Manager Corporate Communications  

 Tel +46 (0)46-19 11 22   

(Corp. Reg. No. 556223-9227)

PO Box 724, SE-220 07 Lund                                                                                              

Tel +46 (0)46-19 20 00

Fax +46 (0)46-19 20 50

 

This report is also available at  www.activebiotech.com